Cytokinetics Incorporated (CYTK) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
Cytokinetics Incorporated's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period
Return on Investment, Quarterly Results, Trends, Rankings, Statistics
What is Cytokinetics Incorporated's ROI in the second quarter of 2026?
Cytokinetics Incorporated recorded a cumulative net loss of $-894 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -67.04%.
Within the Healthcare sector 540 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3578 to 3892.
Impact Assessment of Cytokinetics’ Strategic Developments and Talent AcquisitionCytokinetics Announces Drug Licensing Deal with SanofiOn December 20, 2024, Cytokinetics, a California-based biopharmaceutical company, announced an exclusive agreement with Sanofi for the development and commercialization of aficamten, a next-in-class cardiac myosin inhibitor. This drug aims to treat patients with both obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) in Greater China. Aficamten, sourced from Corxel Pharmaceuticals, has been recognized as a promising therapeutic avenue in the cardiovascular disease space, which could potentially expand the market for Cytokinetics significantly by leveraging Sanofi s established presence in the region.Financial Performance Amidst Strategic PartnershipsDespite the strategic acquisition of aficamten, Cytokinetics reported a cumulative net loss of $576 million for the 12 months ending in the third quarter of 2024, with a detrimental return on investment (ROI) of -55.05%. This financial strain suggests that while the collaboration with Sanofi is promising, it must translate into profitable returns to secure the company s long-term viability. Investors may view such losses with caution, as they indicate the company has not yet reaped the benefits of its innovative approaches or market developments.
Cytokinetics Boosts Employee Incentives with Inducement Grants in Nasdaq Listing Move In a move aimed at attracting and retaining top talent, Cytokinetics, Incorporated (Nasdaq: CYTK) has announced the granting of stock options and restricted stock units (RSUs) to 16 newly employed individuals. The inducement grants, made under Nasdaq Listing Rule 5635(C)(4), are intended to serve as a material incentive for these employees, whose tenure with the company commenced in July 2024. The biopharmaceutical company, headquartered in South San Francisco, has stepped up its efforts to bolster its staff amid an increasingly competitive industry landscape. By providing attractive inducements to new employees, Cytokinetics aims to secure skilled professionals who can help drive the company s growth and innovation in the rapidly evolving pharmaceutical sector.
In an impressive move, Cytokinetics, Incorporated (Nasdaq: CYTK) recently announced the provision of inducement grants to a select group of employees. These grants consist of stock options, restricted stock units (RSUs), and performance stock units (PSUs), demonstrating the company s commitment to attracting and retaining top talent. With a total of 48,453 shares of common stock, 31,460 RSUs, and 5,537 PSUs granted, Cytokinetics aims to motivate and reward these employees, whose employment began in June 2024. While the announcement of these inducement grants is exciting, it comes at a time when the company is also grappling with financial challenges. Cytokinetics recorded a cumulative net loss of $527 million in the 12 months ending in the third quarter of 2023. This resulted in a negative return on investment (ROI) of -67.49%, positioning the company behind 675 other healthcare sector firms that achieved higher ROIs.
Cytokinetics, Incorporated, a biopharmaceutical company, recently announced its partnership with the European Organisation for Rare Diseases (EURORDIS) and the National Organization for Rare Disorders (NORD) in support of Rare Disease Day. This international campaign aims to increase awareness and public understanding of rare diseases, highlighting the challenges faced by over 300 million people living with such conditions worldwide. Additionally, Cytokinetics financial performance has been notably affected, as the company recorded a cumulative net loss of $527 million during the 12-month period ending in the third quarter of 2023, contributing to a negative return on investment (ROI) of -67.49%. Cytokinetics Commitment to Rare Disease Day: Cytokinetics decision to join the EURORDIS and NORD in recognizing Rare Disease Day demonstrates the company s dedication to raising awareness and promoting better access to diagnosis, treatment, care, and social opportunities for individuals with rare diseases. By participating in this global initiative, Cytokinetics aims to contribute to a more equitable healthcare landscape and improve the lives of millions of people affected by rare diseases.
Financial Statements
Cytokinetics Incorporated's II. Quarter Investments
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
